INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC

Core Points - Holzer & Holzer, LLC is investigating Replimune Group, Inc. for potential compliance issues with federal securities laws following the receipt of a Complete Response Letter from the FDA regarding its Biologics License Application for RP1 [1] - The FDA's Complete Response Letter indicated that the IGNYTE trial was not considered adequate to provide substantial evidence of effectiveness for the treatment of advanced melanoma [1] - Following the announcement of the CRL, Replimune's stock price experienced a decline [1] Company Information - Replimune Group, Inc. is focused on developing treatments for advanced melanoma, specifically through the use of RP1 in combination with nivolumab [1] - The company is publicly traded on NASDAQ under the ticker REPL [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]